424 related articles for article (PubMed ID: 16572426)
1. Tissue array analysis of expression microarray candidates identifies markers associated with tumor grade and outcome in serous epithelial ovarian cancer.
Ouellet V; Guyot MC; Le Page C; Filali-Mouhim A; Lussier C; Tonin PN; Provencher DM; Mes-Masson AM
Int J Cancer; 2006 Aug; 119(3):599-607. PubMed ID: 16572426
[TBL] [Abstract][Full Text] [Related]
2. Glycodelin in ovarian serous carcinoma: association with differentiation and survival.
Mandelin E; Lassus H; Seppälä M; Leminen A; Gustafsson JA; Cheng G; Bützow R; Koistinen R
Cancer Res; 2003 Oct; 63(19):6258-64. PubMed ID: 14559812
[TBL] [Abstract][Full Text] [Related]
3. Characterization of the 19q12 amplification including CCNE1 and URI in different epithelial ovarian cancer subtypes.
Noske A; Henricksen LA; LaFleur B; Zimmermann AK; Tubbs A; Singh S; Storz M; Fink D; Moch H
Exp Mol Pathol; 2015 Feb; 98(1):47-54. PubMed ID: 25527175
[TBL] [Abstract][Full Text] [Related]
4. Significance of cell cycle regulatory proteins as malignant and prognostic biomarkers in ovarian epithelial tumors.
Lee YH; Heo JH; Kim TH; Kang H; Kim G; Kim J; Cho SH; An HJ
Int J Gynecol Pathol; 2011 May; 30(3):205-17. PubMed ID: 21464733
[TBL] [Abstract][Full Text] [Related]
5. Combined CCNE1 high-level amplification and overexpression is associated with unfavourable outcome in tubo-ovarian high-grade serous carcinoma.
Chan AM; Enwere E; McIntyre JB; Wilson H; Nwaroh C; Wiebe N; Ou Y; Liu S; Wiedemeyer K; Rambau PF; Grevers X; Morris DG; Neri P; Gilks CB; Visser F; Le N; Luo L; Cook LS; Köbel M
J Pathol Clin Res; 2020 Oct; 6(4):252-262. PubMed ID: 32391646
[TBL] [Abstract][Full Text] [Related]
6. Expression of Interactive Genes Associated with Apoptosis and Their Prognostic Value for Ovarian Serous Adenocarcinoma.
Shin K; Kim KH; Yoon MS; Suh DS; Lee JY; Kim A; Eo W
Adv Clin Exp Med; 2016; 25(3):513-21. PubMed ID: 27629740
[TBL] [Abstract][Full Text] [Related]
7. Analysis of gene amplification and prognostic markers in ovarian cancer using comparative genomic hybridization for microarrays and immunohistochemical analysis for tissue microarrays.
Mayr D; Kanitz V; Anderegg B; Luthardt B; Engel J; Löhrs U; Amann G; Diebold J
Am J Clin Pathol; 2006 Jul; 126(1):101-9. PubMed ID: 16753589
[TBL] [Abstract][Full Text] [Related]
8. CCNE1 and BRD4 co-amplification in high-grade serous ovarian cancer is associated with poor clinical outcomes.
Petersen S; Wilson AJ; Hirst J; Roby KF; Fadare O; Crispens MA; Beeghly-Fadiel A; Khabele D
Gynecol Oncol; 2020 May; 157(2):405-410. PubMed ID: 32044108
[TBL] [Abstract][Full Text] [Related]
9. Global gene expression profiling identifies ALDH2, CCNE1 and SMAD3 as potential prognostic markers in upper tract urothelial carcinoma.
Wu S; Chen J; Dong P; Zhang S; He Y; Sun L; Zhu J; Cheng Y; Li X; Tang A; Huang Y; Gui Y; Liu C; Yang G; Zhou F; Cai Z; Wang R
BMC Cancer; 2014 Nov; 14():836. PubMed ID: 25408144
[TBL] [Abstract][Full Text] [Related]
10. Amplicon profiles in ovarian serous carcinomas.
Nakayama K; Nakayama N; Jinawath N; Salani R; Kurman RJ; Shih IeM; Wang TL
Int J Cancer; 2007 Jun; 120(12):2613-7. PubMed ID: 17351921
[TBL] [Abstract][Full Text] [Related]
11. Characterization of active mitogen-activated protein kinase in ovarian serous carcinomas.
Hsu CY; Bristow R; Cha MS; Wang BG; Ho CL; Kurman RJ; Wang TL; Shih IeM
Clin Cancer Res; 2004 Oct; 10(19):6432-6. PubMed ID: 15475429
[TBL] [Abstract][Full Text] [Related]
12. Cyclin E1 (CCNE1) as independent positive prognostic factor in advanced stage serous ovarian cancer patients - a study of the OVCAD consortium.
Pils D; Bachmayr-Heyda A; Auer K; Svoboda M; Auner V; Hager G; Obermayr E; Reiner A; Reinthaller A; Speiser P; Braicu I; Sehouli J; Lambrechts S; Vergote I; Mahner S; Berger A; Cacsire Castillo-Tong D; Zeillinger R
Eur J Cancer; 2014 Jan; 50(1):99-110. PubMed ID: 24176298
[TBL] [Abstract][Full Text] [Related]
13. Expression of PH Domain Leucine-rich Repeat Protein Phosphatase, Forkhead Homeobox Type O 3a and RAD51, and their Relationships with Clinicopathologic Features and Prognosis in Ovarian Serous Adenocarcinoma.
Zhang J; Wang JC; Li YH; Wang RX; Fan XM
Chin Med J (Engl); 2017 Feb; 130(3):280-287. PubMed ID: 28139510
[TBL] [Abstract][Full Text] [Related]
14. Clinicopathological significance of DEK overexpression in serous ovarian tumors.
Han S; Xuan Y; Liu S; Zhang M; Jin D; Jin R; Lin Z
Pathol Int; 2009 Jul; 59(7):443-7. PubMed ID: 19563407
[TBL] [Abstract][Full Text] [Related]
15. Loss of p16INK4A expression in low-grade ovarian serous carcinomas.
Schlosshauer PW; Deligdisch L; Penault-Llorca F; Fatemi D; Qiao R; Yao S; Pearl M; Yang Z; Sheng T; Dong J
Int J Gynecol Pathol; 2011 Jan; 30(1):22-9. PubMed ID: 21131838
[TBL] [Abstract][Full Text] [Related]
16. Prognostic significance of Notch 3 gene expression in ovarian serous carcinoma.
Jung SG; Kwon YD; Song JA; Back MJ; Lee SY; Lee C; Hwang YY; An HJ
Cancer Sci; 2010 Sep; 101(9):1977-83. PubMed ID: 20624166
[TBL] [Abstract][Full Text] [Related]
17. [Clinicopathologic analysis and expression of cyclin D1 and p53 of ovarian borderline tumors and carcinomas].
Shao HL; Shen DH; Xue WC; Li Y; Yu YZ
Zhonghua Fu Chan Ke Za Zhi; 2007 Apr; 42(4):227-32. PubMed ID: 17631760
[TBL] [Abstract][Full Text] [Related]
18. The NER-related gene GTF2H5 predicts survival in high-grade serous ovarian cancer patients.
Gayarre J; Kamieniak MM; Cazorla-Jiménez A; Muñoz-Repeto I; Borrego S; García-Donas J; Hernando S; Robles-Díaz L; García-Bueno JM; Ramón Y Cajal T; Hernández-Agudo E; Heredia Soto V; Márquez-Rodas I; Echarri MJ; Lacambra-Calvet C; Sáez R; Cusidó M; Redondo A; Paz-Ares L; Hardisson D; Mendiola M; Palacios J; Benítez J; García MJ
J Gynecol Oncol; 2016 Jan; 27(1):e7. PubMed ID: 26463438
[TBL] [Abstract][Full Text] [Related]
19. Expression profiling of serous low malignant potential, low-grade, and high-grade tumors of the ovary.
Bonome T; Lee JY; Park DC; Radonovich M; Pise-Masison C; Brady J; Gardner GJ; Hao K; Wong WH; Barrett JC; Lu KH; Sood AK; Gershenson DM; Mok SC; Birrer MJ
Cancer Res; 2005 Nov; 65(22):10602-12. PubMed ID: 16288054
[TBL] [Abstract][Full Text] [Related]
20. Characterization of the molecular differences between ovarian endometrioid carcinoma and ovarian serous carcinoma.
Madore J; Ren F; Filali-Mouhim A; Sanchez L; Köbel M; Tonin PN; Huntsman D; Provencher DM; Mes-Masson AM
J Pathol; 2010 Feb; 220(3):392-400. PubMed ID: 19967725
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
